Elafibranor, targeting PPARα/δ, resolved NASH without fibrosis worsening in a phase IIb trial (NCT01694849) [143], but it failed to achieve NASH resolution without worsening fibrosis in a phase III trial and was terminated [144]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.